Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
Novo Nordisk (Denmark) · University of Gothenburg · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
102
total citations
- FWCI
- 157.64
- Percentile
- 100%
- References
- 44
Citations per year
Authors
10Topics & keywords
Topics
Keywords
- Semaglutide
- Medicine
- Type 2 diabetes
- Placebo
- STRIDE
- Arterial disease
- Diabetes mellitus
- Physical therapy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.